Brief: 3D Medicines Updates On Exclusive License Agreement Between Co And Sellas Life Sciences
27/12/2023 24:35
Dec 27 (Reuters) - 3D Medicines Inc 1244.HK :
* UPDATES ON EXCLUSIVE LICENSE AGREEMENT BETWEEN CO AND
SELLAS
LIFE SCIENCES
* PRESENTLY UNABLE TO ASSESS POTENTIAL IMPACT OF
ARBITRATION, IF
ANY, ON GROUP AT THIS STAGE
* CONSIDERS THAT CLAIMS AND ALLEGATIONS FROM CLAIMANTS ARE
GROUNDLESS AND UNJUSTIFIED
* WILL STRENUOUSLY CONTEST ARBITRATION
Further company coverage: 1244.HK
Recent news on 3D Medicines
See all newsBrief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
Brief: 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Brief: 3D Medicines Inc Enters Strategic Agreement With Catug Biotechnology